Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata

被引：0
|
作者：
Moe Sakakibara
Harunari Shimoyama
Mami Nomura
Chikako Nakashima
Megumi Hirabayashi
Yoshihiro Sei
Yoshihiro Kuwano
机构：
[1] Teikyo University School of Medicine,Department of Dermatology, Mizonokuchi Hospital
来源：
European Journal of Dermatology | 2019年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：436 / 437
页数：1
相关论文
共 50 条
  • [21] Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
    Mease P.J.
    Rheumatology and Therapy, 2014, 1 (1) : 1 - 20
  • [22] Improvement of severe alopecia areata in an adolescent patient on upadacitinib
    Ha, Gi Ung
    Kim, Jin Ho
    Jang, Yong Hyun
    PEDIATRIC DERMATOLOGY, 2024, 41 (02) : 356 - 358
  • [23] The potential role of roflumilast: The new phosphodiesterase-4 inhibitor
    Karish, Sarah B.
    Gagnon, James M.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (06) : 1096 - 1104
  • [24] Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease
    Boswell-Smith, Victoria
    Page, Clive P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (09) : 1105 - 1113
  • [25] Practical enantioselective process for a chiral phosphodiesterase-4 inhibitor
    Chen, CY
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (06) : 709 - 722
  • [26] Efficacy and anti-inflammation activity of a selective phosphodiesterase-4 inhibitor cilomilast in treatment of COPD
    Wang, CZ
    Song, YX
    Liao, XQ
    Li, Q
    Wang, JP
    Zhao, ZQ
    CHEST, 2005, 128 (04) : 262S - 262S
  • [27] Efficacy of baricitinib in treating severe alopecia areata: a retrospective study
    Li, Wen-fei
    Tu, Ying
    Yang, Zheng-hui
    Hua, Pi-yan
    Yao, Qiu-yan
    Gu, Hua
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 317 (01)
  • [28] Efficacy and Tolerability of Methotrexate in the Treatment of Severe Paediatric Alopecia Areata
    Albela, Henrietta
    Begum, Sabeera
    Wee, Ai Leen
    Ponnuthurai, Nirmala
    Leong, Kin Fon
    SKIN APPENDAGE DISORDERS, 2022, 8 (03) : 206 - 210
  • [29] Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, by body region and PASI components in patients with moderate to severe plaque psoriasis (ESTEEM 1)
    Kircik, Leon
    Weiss, Jonathan
    Philipp, Sandra
    Goodfield, Mark
    Hu, ChiaChi
    Day, Robert
    Foley, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB234 - AB234
  • [30] Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
    Philip J. Mease
    Rheumatology and Therapy, 2015, 2 (1) : 97 - 97
12345